Trial Profile
A Prospective Multicenter Observational Study for Characterization of Renal Function G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir (Primary) ; Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Mar 2019 Status changed from active, no longer recruiting to completed.
- 15 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2017 New trial record